List of Alecensa drug patents

Alecensa is owned by Hoffmann-La Roche.

Alecensa contains Alectinib Hydrochloride.

Alecensa has a total of 5 drug patents out of which 0 drug patents have expired.

Alecensa was authorised for market use on 11 December, 2015.

Alecensa is available in capsule;oral dosage forms.

The generics of Alecensa are possible to be released after 24 April, 2035.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents protects the active chemical substance. Only patent owner can launch products that use this active substance.
US9126931 HOFFMANN-LA ROCHE Tetracyclic compound
May, 2031

(8 years from now)

These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9440922 HOFFMANN-LA ROCHE Tetracyclic compound
Jun, 2030

(7 years from now)

US9365514 HOFFMANN-LA ROCHE Composition comprising tetracyclic compound
Mar, 2032

(9 years from now)

US10350214 HOFFMANN-LA ROCHE Preparation containing tetracyclic compound at high dose
Apr, 2035

(12 years from now)

US11433076 HOFFMANN-LA ROCHE Preparation containing tetracyclic compound at high dose
Apr, 2035

(12 years from now)

Exclusivity Exclusivity Expiration
Orphan Drug Exclusivity (ODE) Nov 6, 2024

Drugs and Companies using ALECTINIB HYDROCHLORIDE ingredient

Market Authorisation Date: 11 December, 2015

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of ALECENSA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic

Other things you might be interested in